Blueberry Therapeutics Ltd

Blueberry Therapeutics Ltd is a modern drug discovery and development company, founded in 2011, in the United Kingdom. The company prioritizes the well-being of patients, employees, investors, and partners. With a focus on skin diseases treatments, they utilize innovative preclinical research technologies to develop potent and safe molecules for clinical development, aiming to create new and more effective medicines. Blueberry has recently received a £750.00K Venture Round investment on 08 June 2021 from NPIF Maven Equity Finance. The company's approach to utilizing smart, agile clinical designs is aimed at delivering high-quality trials more rapidly and with reduced development costs. Their programs are targeted at addressing Onychomycosis, Tinea Pedis, Acne, and Atopic Dermatitis. By focusing on well-validated drug targets and ensuring low toxicity liability of candidate molecules, Blueberry aims to mitigate reasons for drug failures in the clinic. Their ultimate goal is to progress new therapies to clinical proof-of-concepts and beyond with appropriate, effective, and safe doses, while securing full regulatory and ethical approval.